5TH ANNUAL MEETING

NEW TECHNOLOGIES AND STRATEGIES TO FIGHT CANCER

OCTOBER 28-30, 2020 - VIRTUAL MODE

ORGANIZED BY

IEO
Istituto Europeo di Oncologia

UNIVERSITÀ DEGLI STUDI DI MILANO
COMMITTEES

ALLIANCE AGAINST CANCER
RUGGERO DE MARIA, ROME
PAOLO DE PAOLI, ROME

EXECUTIVE COMMITTEE
GENNARO CILIBERTO, ROME
PIER GIUSEPPE PELICCI, MILAN
ANNA SAPINO, TURIN

HOST INSTITUTIONS
EUROPEAN INSTITUTE OF ONCOLOGY - IEO IRCCS, MILAN
UNIVERSITY OF MILAN

COORDINATOR
ROBERTO ORECCHIA, MILAN

SCIENTIFIC COMMITTEE
GIOVANNI APOLONE, MILAN
GERARDO BOTTI, NAPLES
GENNARO CILIBERTO, ROME
SILVIA FRANCESCHI, AVIANO - PORDENONE
GIOVANNI MARTINELLI, MELDOLA - FORLÌ CESENA
ANGELO PARADISO, BARI
PIER GIUSEPPE PELICCI, MILAN
PAOLO PRONZATO, GENOVA
GIANDOMENICO RUSSO, ROME
ANNA SAPINO, CANDIOLO - TURIN

ORGANIZING COMMITTEE AND PRESS OFFICE
MYRIAM ALCALAY, MILAN
MASSIMO BONI, ROME
CRISTINA BONVICINI, MILAN
EVA BRUSCHINI, MILAN
ENRICO DERENZINI, MILAN
LUCA MAZZARELLA, MILAN

direzione.scientifica@ieo.it - press@alleanzacontroilcancro.it
OPENING SESSION AUTHORITIES

Roberto Orecchia, Scientific Director, IEO IRCCS
Ruggero De Maria, President, Alliance Against Cancer
Maria Pia Abbracchio, Pro-Rector, Milan University
Giovanni Leonardi, General Director of Research and Innovation in Health Innovation, Italian MoH
Mauro Melis, Chief Executive Officer, IEO IRCCS
Giuseppe Sala, Mayor of Milan

SESSION 1: PRE-CLINICAL BREAKTHROUGHS

Intra-tumour heterogeneity; microenvironment; mechanisms of metastasis and drug-resistance; novel therapeutic approaches.

Chairs
Paolo Dellabona, Director, Division of Immunology, Transplantation and Infectious Diseases and Research, HSR IRCCS
Alberto Mantovani, Scientific Director, Humanitas IRCCS
Gioacchino Natoli, Department of Experimental Oncology, IEO IRCCS

09:00-09:45
Yinyin Yuan, ICR-The Institute of Cancer Research
Deciphering the tumor microenvironment with computational pathology

09:45-10:00
Davide Ceresa, Ospedale Policlinico San Martino, Genova
Liquid biopsy to evaluate triple negative breast cancer heterogeneity: an innovative study using genetic barcoding

(*) To be confirmed
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:15</td>
<td>Elena Magrini, Humanitas IRCCS</td>
<td>Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression</td>
</tr>
<tr>
<td>10:15-10:30</td>
<td>Roberta Noberini, IEO IRCCS</td>
<td>Epi-proteomics profiling of clinical samples reveals novel hallmarks of cancer and biomarkers for breast cancer patient stratification</td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>Samuele Notarbartolo, INGM</td>
<td>Phenotypic and functional characterization of infiltrating effector T cell heterogeneity in primary and metastatic CRC</td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>Mariangela Russo, Candiolo IRCCS</td>
<td>Stress-induced mutagenesis favors adaptation of colorectal cancers in response to targeted therapies</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Annalisa Tocci, IRE IRCCS</td>
<td>hMENA11a loss activates Type I IFN and inflammatory pathways, and in turn PD-L1 expression, by activating the viral sensor RIG-I</td>
</tr>
<tr>
<td>11:30-12:45</td>
<td>Round Table</td>
<td>Current and up-coming technologies to study intra-tumor genetic and phenotypic heterogeneity</td>
</tr>
</tbody>
</table>

**Discussants**
- Andrea Biondi, Director, Department of Pediatric, Fondazione MBBM/Ospedale San Gerardo and University of Milano-Bicocca
- Massimiliano Pagani, IFOM and Milan University
- Angela Santoni, Scientific Director, Istituto Pasteur Italia-Fond. Cenci Bolognetti
- TBD, Illumina Italy srl (*)
- Luca Quagliata, Thermo Fisher Scientific

**12:45-13:30**
**Selected Posters**
- Fabrizio Antonangeli, Uni Roma/Neuromed Pozzilli
  Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance

(*) To be confirmed
12:52 | Natalia Di Ianni, Besta IRCCS
Radiotherapy treatment in combination with Dendritic Cell Immunotherapy polarizes microglia from M2 to M1 phenotype

12:59 | Stefania Faletti, IEO IRCCS
LSD1 and the adaptive integrated stress response: a novel pathway maintaining tumor initiating cells in human GBM

13:06 | Eugenia Giuliani, Sapienza University
Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response

13:13 | Barbara Pasculli, IRCCS Casa Sollievo della Sofferenza
Clinical association of mir-155-5p with breast cancer and its putative relevance for the treatment with PARP inhibitors

13:20 | Giorgia Simonetti, IRST IRCCS
Metabolomics identifies a subgroup of NPM1-mutant acute myeloid leukemia with genomic and transcriptomic specificities

13:30-15:30 | HIGHLIGHT SESSION 1: COVID-19 AND CANCER
Biology of COVID19 and diverse patient responses; COVID19 and cancer links

Chairs | Silvio Brusaferro, President, Istituto Superiore di Sanità,
Franco Locatelli, President, Consiglio Superiore della Sanità, Italian MoH

13:30-14:15 | Sergio Abrignani, Scientific director, INGM and University of Milan
Effector and memory lymphocyte responses elicited by Sars-Cov2 infection in man

14:15-15:30 | Round Table
Cancer patient challenges: limited access to cancer screenings and care, worse Covid-19 prognosis

Discussants | Giovanni Rezza, Direttore Generale Prevenzione, Ministero della Salute
Giuseppe Ippolito, Scientific Director, INMI Ospedale Spallanzani

(*) To be confirmed
15:30-20:00  
**SESSION 2: CANCER PREVENTION AND EARLY-DETECTION**  
Assessment of Genetic and Environmental cancer-risk factors; Early-diagnosis biomarkers

**Chairs**  
Silvia Franceschi, Scientific Director, CRO IRCCS  
Giuseppe Opocher, Scientific Director, IOV IRCCS  
Giuseppe Remuzzi, Scientific Director, Mario Negri Institute for Pharmacological Research IRCCS

15:30-16:15  
**Annarosa Del Mistro**, IOV IRCCS  
Towards universal prevention of a tumour: the case of HPV and cervical cancer

16:15-17:00  
**Maurizio D’Incalci**, Mario Negri Institute for Pharmacological Research IRCCS  
Early Diagnosis of Ovarian Cancer by the Analysis of TP53 Clonal Variants in cervical cells.

17:00-17:15  
**Silvia Cascianelli**, Politecnico Milano  
Boosting perspectives for breast cancer intrinsic subtyping on RNA-sequencing data

17:15-17:30  
**Mara Colombo**, INT IRCCS  
BRCA gene splicing analysis identified a large number of pathogenic variants in Italian breast/ovarian cancer families

17:30-17:45  
**Sara Raimondi**, IEO IRCCS  
Association of MC1R genotype with melanoma risk according to sun exposure

17:45-18:00  
**Andrew M. Thomas**, CIBIO  
Gut microbial signatures for colorectal cancer detection within and across cohorts

18:00-19:15  
**Round Table**  
Personal-data sharing, property and privacy

(*) To be confirmed
Discussants

Roberto de Miro, FAVO- Federazione Volontari Italiani
Annarosa Del Mistro, IOV IRCCS
Maurizio D’Incalci, Mario Negri Institute for Pharmacological Research IRCCS
Stefano Ferretti, AIRTUM-Associazione Italiana Registri Tumori
Maurizio Genuardi, Policlinico Gemelli IRCCS
Carlo La Vecchia, Milan University

19:15-20:00

Selected Posters

19:15
Matteo Allegretti, IRE IRCCS
LiqBreasTrack: liquid biopsy in T-DM1- treated HER2+ breast cancer patients

19:23
Tiziana Bonaldi, IEO IRCCS
Identification of biomarkers for lung cancer early diagnosis by MS-based serum proteomics

19:31
Evaristo Cisbani, ISS
Innovative molecular breast imaging device for early cancer diagnosis

19:39
Luigino Dal Maso, CRO IRCCS
Indicators of cancer cure for European patients: Results from the EUROCARE-5 study

19:47
Giuseppe De Luca, S. Martino IRCCS
Going beyond WGA: Optimization of a Molecular Tagging-Based NGS Protocol for CTCs

Mutational Profiling

(*) To be confirmed
SESSION 3: INNOVATIVE TREATMENTS
Genomic-based Clinical Trials, Immunotherapy, Radiotherapy

Chairs
Lisa Licitra, Scientific Director, CNAO
Giovanni Martinelli, Scientific Director, IRST IRCCS
Giovanni Scambia, Scientific Director, Policlinico Gemelli IRCCS

08:30-09:15
Angelica Facoetti, CNAO
Carbon ion therapy: new insights in the biological mechanisms of tumor control

09:15-10:00
Christophe Le Tourneau, D3i, Institut Curie
Drug development in oncology in the era of precision medicine

10:00-10:15
Silvia Bortolussi, INFN Pavia
Boron Neutron Capture Therapy: an emerging selective form of hadrontherapy as a therapeutic option for disseminated tumours

10:15-10:30
Antonio Camera, OPBG IRCCS
GD2-specific chimeric antigen receptor (CAR) T cells incorporating CD28.4-1BB costimulatory domains for treatment of GD2+ sarcomas

10:30-10:45
Gloria Deflanti, HSR IRCCS
Dual targeting of cancer and suppressive myeloid cells by tumor-redirected iNKT cells and antigen-carrying microparticles

10:45-11:00
Simona Manni, OPBG IRCCS
Strategies to increase CAR T-cell safety and to prevent epitope masking in CAR+ B-cell leukemia blasts

(*) To be confirmed
11:00-12:15  
**Round Table**  
New treatments: Research Priorities  

**Discussants**  
- Angelica Facoetti, CNAO  
- Christophe Le Tourneau, Institut Curie  
- Corrado Tarella, IEO IRCCS  
- Giampaolo Tortora, Policlinico Gemelli IRCCS  
- Clemens Schmitt, MDC Berlin  
- Pier Luigi Zinzani, Bologna University  

12:15-13:00  
**Selected Posters**  

12:15  
**Alfredo Budillon**, INT “Pascale”, IRCCS  
**Neoadjuvant nivolumab in early stage colon cancer induces promising tumor regression and T cell infiltration**  

12:22  
**Marika Guercio**, OPBG IRCCS  
**CAR T-cell therapy for the treatment of Germ Cell Tumors (GCTs) with heterogeneous tumor antigen expression**  

12:29  
**Angela Di Giannatale/Luca Boldrini**, OPBG IRCCS  
**Radiogenomics prediction of MYCN status in neuroblastoma: a hypothesis generating study**  

12:36  
**Giuseppe Fanetti**, CRO IRCCS  
**Comorbidities and Cetuximab concomitantly to radiation for platinum-unfit head and neck squamous cell carcinoma patients**  

12:43  
**Maria B. Ligabue**, Ausl–IRCCS Reggio Emilia  
**Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial**  

12:50  
**Francesca Paolini/Aldo Venuti**, IRE IRCCS  
**An Old Idea Reinvigorated: Plant-Derived Hpv Chimeric Vaccines For Cancer Treatment.**  

(*) To be confirmed
13:00-13:45  
**Special Lecture Communicating Cancer Research To the public**  
*Daniela Ovadia*, Fondamentale AIRC  
Introduced by *Anna Sapino*, Scientific Director, Candiolo IRCCS

13:45-14:30  
**Special Lecture: Patient involvement and empowerment**  
*Salvo Testa*, President, Mutagens Foundation  
Introduced by *Francesco de Lorenzo*, President, AImaC  
*Gabriella Pravettoni*, IEO IRCCS and Milan University

14:30-17:30  
**HIGHLIGHT SESSION 2: HIGH-DEFINITION ONCOLOGY**  
National and International Data-sharing infrastructures; Real World Data; Outcomes Research  
**Chairs**  
*Gennaro Ciliberto*, Scientific Director, IRE IRCCS  
*Pier Giuseppe Pelicci*, IEO and Scientific Coordinator ACC  
*Fabrizio Tagliavini*, Scientific Director, Besta IRCCS

14:30-15:15  
*David Kerr*, Radcliffe Department of Medicine, University of Oxford  
**International collaboration to collect real time anti cancer drug delivery data**

15:15-15:35  
*Letizia Tanca*, Politecnico Milano  
**The Health Big Data Project: Challenges and Approaches**

15:35-15:55  
*Piers Mahon*, Senior Principal and European Leader, Oncology Evidence Networks at IQVIA  
**DIGICORE: an international real world collaboration for translational and outcomes research in precision oncology**

15:55-16:15  
*Giuseppe Testa*, President, ACC GDPR Committee; IEO IRCCS; Milan University and Human Technopole  
**Making the most of GDPR: the national ACC-GDPR Commission and the contemporary research ecosystem,**

(*) To be confirmed
16:15-17:30

Round Table

**Discussants**
- Francesco Profumo, Fondazione Compagnia SanPaolo
- Anna Paganoni, Politecnico Milano
- Salvatore Rossi, President, Telecom Italia
- Andrea Di Santo, Cassa Depositi e Prestiti
- Sergio Liberatore, Italy General Manager, IQVIA
- Vincenzo Valentini, IRCCS Policlinico Gemelli
- Filippo De Braud, INT IRCCS and University of Milan
- Antonio Zoccoli, INFN

**Invited speakers**
- Highlight Session 2

17:30-19:00

Discussion Forum: Role of Collaborative Networks in cancer research and practice.

**Chairs**
- Ruggero De Maria, President, Alliance Against Cancer
- Giovanni Leonardi, General Director of Research and Innovation in Health

**Discussants**
- Nicholas Jones, Cancer Grand Challenge programme, University of Manchester
- Giulio Draetta, Senior Vice President and Chief Scientific Officer, MD Anderson Cancer Center, Houston, TX
- Jean-Yves Blay, President, Unicancer; General Director, Centre Léon Bérard, Lyon; Director, EURACAN
- Simon Oberst, Chair, OECI Accreditation Board, and Director of Clinical Development, the CRUK Cambridge Centre
- Walter Ricciardi, UE Mission Board for Cancer and Scientific Director, ICS Maugeri IRCCS

(*) To be confirmed
## HIGHLIGHT SESSION 3: ACCESS OF PATIENTS TO GENOMIC SCREENS AND NEW DRUGS

**Chairs**

- **Gennaro Ciliberto**, Scientific Director, IRE and Alliance Against Cancer
- **Ruggero De Maria**, President, Alliance Against Cancer
- **Pier Giuseppe Pelicci**, Scientific Coordinator, Alliance Against Cancer; Director of Research, IEO IRCCS; University of Milan

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
</table>
| 08:30-09:15   | **Fabien Calvo**,  
Gustave Roussy | **Genomics and Drug developments: the two revolutions in the last 20 years in cancer management and care** |
| 09:15-09:35   | **Vanessa Gregorc**,  
HSR | **The ACC Lung cancer trial** |
| 09:35-09:55   | **Domenica LoRusso**,  
IRCCS Policlinico Gemelli | **The ACC GerSom trial** |
| 09:55-10:15   | **Concetta Quintarelli**,  
Bambino Gesù Hospital | **CAR T program in ACC: activity framework and advances** |
| 10:15-10:35   | **Luca Mazzarella**,  
IEO IRCCS | **The Liquid Biopsy (OncoNGS Consortium)** |
| 10:35-10:55   | **Giovanni Tonon**,  
HSR Milan | **One Millione Genome Project** |
| 10:55-11:15   | **Nello Martini**,  
Fondazione Ricerca e Salute | **ACC-AIOM project on mutational oncology** |
| 11:15-11:35   | **Sandro Pignata**,  
Istituto Nazionale TUMORI IRCCS Pascale (video) | **Forza: the ACC clinical research infrastructure** |

(*) To be confirmed
11:35-13:15 Round Table

**Discussants**
- Saverio Cinieri, AION (video)
- Nicola Magrini, General Director, AIFA (*)
- Giselda Scalera, Research and Innovation in Health
- Paolo Marchetti, Direttore Polo Oncologico Università La Sapienza
- Alberto Bardelli, Candiolo IRCCS

**Invited speakers**, Highlight Session 3

13:15-14:15 ACC Priorities

**Chairs**
- Ruggero De Maria, President, Alliance Against Cancer
- Paolo De Paoli, General Manager, Alliance Against Cancer

13:15-13:45

**Pier Giuseppe Pelicci**, Scientific Coordinator, Alliance Against Cancer; Director, Research Area IEO IRCCS; University of Milan

13:45-14:15 Discussion

14:15-14:45 Meeting Conclusions

**Ruggero De Maria**, President, Alliance Against Cancer

**Introduced by**
- Giovanni Leonardi, General Director of Research and Innovation in Health

14:45-19:45 ACC WORKSHOP

**2020 Activity-report and 2021 scientific plans**

**Workshop Coordinators**
- Myriam Alcalay, IEO IRCCS
- Gennaro Ciliberto, Scientific Director, IRE and Alliance Against Cancer
- Ruggero De Maria, President, Alliance Against Cancer
- Pier Giuseppe Pelicci, Scientific Coordinator, Alliance Against Cancer;
  Director of Research, IEO IRCCS; University of Milan

(*) To be confirmed
14:45-15:05  
Caterina Marchiò, IRCCS Candiolo  
Luca Mazzarella, IEO IRCCS  
Paola Nisticò, IRE Rome  
Luca Boldrini, IRCCS Policlinico Gemelli  
Giulia Buzzatti, San Martino Hospital IRCCS  
Gaetano Finocchiaro, Besta IRCCS  
Gian Domenico Russo, IDI IRCCS  
Roberta Maestro, CRO Aviano IRCCS  
Katia Scotlandi, IOR IRCCS  
Enrico Derenzini, IEO IRCCS  
Enzo Medico, IRCCS Candiolo

15:05-15:25  
WG PATHOLOGY  
WG GENOMICS  
WG IMMUNOTHERAPY  
WG RADIOMICS  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

15:25-15:45  
Paola Nisticò, IRE Rome  
WG IMMUNOTHERAPY  
WG RADIOMICS  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

15:45-16:05  
Luca Boldrini, IRCCS Policlinico Gemelli  
Giulia Buzzatti, San Martino Hospital IRCCS  
Gaetano Finocchiaro, Besta IRCCS  
Gian Domenico Russo, IDI IRCCS  
Roberta Maestro, CRO Aviano IRCCS  
Katia Scotlandi, IOR IRCCS  
Enrico Derenzini, IEO IRCCS  
Enzo Medico, IRCCS Candiolo

16:05-16:25  
WG RADIOMICS  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

16:25-16:45  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

16:45-17:05  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

17:05-17:25  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

17:25-17:45  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

17:45-18:05  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

18:05-18:25  
WG BREAST  
WG GLIOBLASTOMA  
WG MELANOMA  
WG SARCOMA  
WG SKELETAL-MUSCLE TUMORS  
WG ONCO-HEMATOLOGY  
WG COLON

18:25-19:45  
General Discussion

(*) To be confirmed
The largest Italian network for cancer research